Shire Human Genetic Therapies, Inc. 4
4 · Translate Bio, Inc. · Filed Jun 5, 2020
Insider Transaction Report
Form 4
Shire Human Genetic Therapies, Inc.
10% Owner
Transactions
- Sale
Common Stock
2020-06-03$19.75/sh−40,086$791,699→ 6,824,992 total
Footnotes (3)
- [F1]Weighted average of sales prices. Actual prices range from $19.11 to $20.00. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.
- [F2]This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
- [F3]These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.